PAT Soars 128% in Q4, Company Pivots to High-Growth Specialty Diagnostics
Thyrocare Technologies Ltd · THYROCARE · BSE ·
<b>Stellar Financials:</b> For FY'26, Consolidated Revenue grew 21% to ₹829 Cr, and PAT surged 81% to ₹163 Cr. Q4 PAT was up an impressive 128% YoY. <b>Strategic Pivot to Specialty:</b> The company is launching high-margin Genomics and Allergy testing, aiming for this segment to…